Clinical guideline
EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation
HemaSphere · 2026
Studies and guidelines: Blood cancers
66 items with a structured summary · Blood cancers: the complete guide
Clinical guideline
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Leukemia · 2025
Clinical guideline
EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma
Nat Rev Clin Oncol · 2025
Clinical guideline
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Annals of Oncology · 2025
Clinical guideline
Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel
Blood · 2024
Clinical guideline
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Blood · 2022
Clinical guideline
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Leukemia · 2022
Clinical guideline
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Leukemia · 2022
Clinical guideline
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Biology of Blood and Marrow Transplantation · 2019
Clinical guideline
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Blood · 2018
Clinical guideline
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Lancet Oncol · 2014
Clinical guideline
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
J Clin Oncol · 2014
Clinical trial · Phase 3
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
N Engl J Med · 2025
93.9% (ibrutinib–venetoclax), 79.0% (ibrutinib alone), 58.1% (FCR)Five-year progression-free survival
Clinical trial · Phase 3
The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL
Blood · 2025
54.7 vs 17.0 monthsMedian progression-free survival
Clinical trial · Phase 3
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia
Am J Hematol · 2024
14.7 vs 9.6 monthsMedian overall survival
Clinical trial · Phase 3
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma
N Engl J Med · 2024
HR 0.48Progression-free survival (second interim analysis)
Clinical trial · Phase 3
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Lancet Oncol · 2023
74.6% vs 24.8%42-month progression-free survival
Clinical trial · Phase 3
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
Blood · 2022
HR 0.37Progression-free survival
Observational study
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
NEJM Evid · 2022
46% of patientsReclassification compared with IPSS-R
Clinical trial · Phase 3
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
JCO · 2019
0.46 (95% CI 0.34 to 0.62)Progression-free survival (hazard ratio)
Clinical trial · Phase 3
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
N Engl J Med · 2018
82% vs 28%Progression-free survival at 30 months
Meta-analysis
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
JCO · 2017
52.8 vs 23.5 monthsMedian progression-free survival (PFS)
Clinical trial · Phase 3
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
N Engl J Med · 2017
83.3%10-year overall survival (imatinib group)
Clinical trial · Phase 3
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
N Engl J Med · 2015
24.7 vs 14.4 months (VR-CAP vs R-CHOP)Median progression-free survival (independent radiological review)
Clinical trial · Phase 3
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
N Engl J Med · 2015
Median not reached vs 18.9 monthsProgression-free survival (median)
Clinical trial · Phase 3
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Lancet · 2012
40.8% vs 17.1%2-year event-free survival
Observational study
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
JCO · 2012
From 83.7% (1990–1994) to 90.4% (2000–2005)5-year survival
Clinical trial · Phase 3
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
The Lancet Oncology · 2011
42% in both groups (61 patients in the subcutaneous group and 31 patients in the IV group)Overall response rate after four cycles
Clinical trial · Phase 3
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
The Lancet · 2010
65% vs 45%Progression-free survival at 3 years after randomisation
Clinical trial · Phase 3
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
N Engl J Med · 2008
24.0 months vs 16.6 monthsTime to progression
Review article
Hematopoietic Stem-Cell Transplantation
N Engl J Med · 2006
Clinical trial
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
N Engl J Med · 2006
112 of 148 patients (76%)Reduced transfusion needs
Clinical trial
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
N Engl J Med · 2005
38% vs 18% (bortezomib vs dexamethasone)Combined complete and partial response
Clinical trial
Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
N Engl J Med · 2004
63% vs 98% (palifermin vs placebo)Incidence of WHO grade 3 or 4 oral mucositis
Clinical trial · Phase 3
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
N Engl J Med · 2003
87.1% vs 34.7%Major cytogenetic response at 18 months (0 to 35% Philadelphia chromosome-positive metaphases)
Clinical trial
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
N Engl J Med · 2002
76% vs 63% (CHOP with rituximab vs CHOP alone)Complete response rate
Clinical trial
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
JCO · 1998
48%Response rate (intention to treat)
Clinical trial · Phase 3
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
N Engl J Med · 2024
85% vs 68%3-year overall survival
Clinical trial · Phase 3
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
N Engl J Med · 2024
84.3% vs 67.7%48-month progression-free survival
Clinical trial · Phase 3
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
Lancet Haematol · 2024
60% vs 35%Primary endpoint: red blood cell transfusion independence ≥12 weeks with a mean haemoglobin increase ≥1.5 g/dL (weeks 1 to 24)
Clinical trial · Phase 3
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
N Engl J Med · 2020
38% vs 13%Primary endpoint: transfusion independence ≥8 weeks (weeks 1 to 24)
Clinical trial · Phase 3
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
N Engl J Med · 2020
24.7 vs 14.8 monthsMedian overall survival (from randomisation)
Clinical trial · Phase 3
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
The Lancet Haematology · 2020
41% (108 of 263 patients) vs 37% (96 of 259 patients)Overall response (intention-to-treat population)
Clinical trial · Phase 3
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
N Engl J Med · 2017
7.7 months vs 4.0 monthsMedian overall survival
Clinical trial · Phase 3
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
N Engl J Med · 2026
83.4% vs 29.7%36-month progression-free survival
Clinical trial · Phase 3
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
N Engl J Med · 2025
76.5% (vs 66.5% with chemoimmunotherapy)36-month progression-free survival: acalabrutinib-venetoclax
Clinical trial · Phase 3
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
Blood · 2024
76.2 vs 36.4 monthsMedian progression-free survival
Clinical trial · Phase 3
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
N Engl J Med · 2023
47.2 monthsMedian follow-up
Clinical trial
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
N Engl J Med · 2022
39%Complete response
Clinical trial · Phase 3
Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia
N Engl J Med · 2022
HR 0.33Event-free survival
Clinical trial · Phase 1-2
Teclistamab in Relapsed or Refractory Multiple Myeloma
N Engl J Med · 2022
63.0%Overall response rate
Clinical trial · Phase 3
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
N Engl J Med · 2019
9.3 vs 5.6 monthsMedian overall survival
Clinical trial · Phase 3
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
J Clin Oncol · 2018
9.56 vs 5.95 monthsMedian overall survival
Clinical trial · Phase 2
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
N Engl J Med · 2018
81%Overall remission within 3 months
Clinical trial · Phase 3
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
N Engl J Med · 2017
HR for death 0.78Overall survival
Clinical trial · Phase 3
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
N Engl J Med · 2014
Median not reached in the ibrutinib group vs 8.1 months in the ofatumumab groupProgression-free survival (median)
Clinical trial · Phase 3
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
N Engl J Med · 2023
HR 0.26Progression-free survival
Clinical trial · Phase 3
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Lancet · 2023
59% vs 31%Primary endpoint: red blood cell transfusion independence ≥12 weeks with a mean haemoglobin increase ≥1.5 g/dL (weeks 1 to 24)
Clinical trial · Phase 3
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
N Engl J Med · 2023
13.3 vs 4.4 monthsMedian progression-free survival
Clinical trial · Phase 3
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
N Engl J Med · 2022
8.3 vs 2.0 monthsMedian event-free survival
Clinical trial · Phase 3
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
N Engl J Med · 2022
76.7% vs 70.2%2-year progression-free survival
Clinical trial · Phase 3
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
N Engl J Med · 2020
14.7 vs 9.6 monthsMedian overall survival
Clinical trial · Phase 3
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
N Engl J Med · 2019
89.4% vs 72.9%Progression-free survival at 3 years
Clinical trial · Phase 3
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
N Engl J Med · 2019
HR 0.35Progression-free survival
Clinical trial · Phase 3
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
N Engl J Med · 2018
84.9% vs 36.3%2-year progression-free survival rate (investigator-assessed)
Clinical trial · Phase 3
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
The Lancet · 2011
74.9% vs 57.6%Progression-free survival (PFS) (median follow-up 36 months)
Nothing found.